Thromboembolic and bleeding events associated with angiogenesis inhibitors in cancer patients
All VEGF/VEGFRIs were associated with increased ATE and bleeding risk. VEGF/VEGFR-targeted biologics also significantly raise the risk of VTE.
Authors
- Min Zhu (ORCID: https://orcid.org/0000-0002-7043-6569)
- Zhuoling An (ORCID: https://orcid.org/0000-0002-7996-5002)
- Jiawen Yi (ORCID: https://orcid.org/0000-0001-7224-9831)
- Yuhui Zhang (ORCID: https://orcid.org/0000-0002-4373-1845)
- Yixiao Zhang (ORCID: https://orcid.org/0009-0005-5957-1611)
- Yi Zhang (ORCID: https://orcid.org/0000-0001-8806-847X)
- Zhuo Ma (ORCID: https://orcid.org/0000-0002-3424-0139)
- Dan Sun (ORCID: https://orcid.org/0000-0001-5579-511X)
Institutions
- Capital University (US)
- Capital Medical University (CN)
- Aviation General Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1080/14740338.2025.2494688
- Citations
- 2
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- National Natural Science Foundation of China